5-氰基-6-异丙氧基烟酸甲酯 | 1312008-56-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氰基-6-异丙氧基烟酸甲酯
• 英文名称: methyl 5-cyano-6-[(1-methylethyl)oxy]-3-pyridinecarboxylate
• 英文别名: methyl 5-cyano-6-isopropoxynicotinate；methyl 5-cyano-6-propan-2-yloxypyridine-3-carboxylate
• CAS: 1312008-56-2
• 化学式: C₁₁H₁₂N₂O₃
• 分子量: 220.228
• InChiKey: OQUZZBNVPTWCKT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  72.2
• 氢给体数：
  0
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  5-氰基-6-异丙氧基烟酸甲酯 在 吡啶 、 草酰氯 、 水 、 lithium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 9.33h， 生成 1,1-dimethylethyl 7-(5-{5-cyano-6-[(1-methylethyl)oxy]-3-pyridinyl}-1,2,4-oxadiazol-3-yl)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate
  参考文献：
  名称：

  Discovery of a Brain-Penetrant S1P₃-Sparing Direct Agonist of the S1P₁ and S1P₅ Receptors Efficacious at Low Oral Dose

  摘要：

  2-Amino-2-(4-octylphenethyl)propane-1,3-diol 1 (fingolimod, FTY720) has been recently marketed in the United States for the treatment of patients with remitting relapsing multiple sclerosis (RRMS). Its efficacy has been primarily linked to the agonism on T cells of S1P(1), one of the five sphingosine 1-phosphate (S1P) G-protein-coupled receptors, while its cardiovascular side effects have been associated with activity at S1P(3). Emerging data suggest that the ability of this molecule to cross the blood-brain barrier and to interact with both S1P(1) and S1P(5) in the central nervous system (CNS) may contribute to its efficacy in treating patients with RAMS. We have recently disclosed the structure of an advanced, first generation S1P(3)-sparing S1P(1) agonist, a zwitterion with limited CNS exposure. In this Article, we highlight our strategy toward the identification of CNS-penetrant S1P(3)-sparing S1P(1) and S1P5 agonists resulting in the discovery of 5-(3-{2-[2-hydroxy-1- (hydroxymethyl)ethyl]-5-methyl-1,2,3,4-tetrahydro-6-isoquinolinyl}-1,2,4-oxadiazol-5-yl)-2-[(1-methylethyl)oxy]benzonitrile 15. Its exceptional in vivo potency and good pharmacokinetic properties translate into a very low predicted therapeutic dose in human (< 1 mg p.o. once daily).

  DOI：

  10.1021/jm200609t
• 作为产物：
  描述：

  5-溴-6-氯烟酸 在 四(三苯基膦)钯 、 potassium tert-butylate 作用下， 以 N,N-二甲基甲酰胺 、 异丙醇 为溶剂， 反应 30.0h， 生成 5-氰基-6-异丙氧基烟酸甲酯
  参考文献：
  名称：

  [EN] OXADIAZOLE MODULATORS OF S1P METHODS OF MAKING AND USING
  [FR] MODULATEURS D'OXADIAZOLE DE S1P, AINSI QUE PROCÉDÉS DE FABRICATION ET D'UTILISATION CORRESPONDANTS

  摘要：

  这项发明涉及公式（I）的化合物：其中每个变量在此定义，以及制备和使用这些化合物作为S1P1和/或S1P5激动剂的方法，例如用于治疗移植物抗宿主病和自身免疫疾病。

  公开号：

  WO2017004608A1

文献信息

• [EN] OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS<br/>[FR] DÉRIVÉS D'INDAZOLE SUBSTITUÉS PAR OXADIAZOLE DESTINÉS À ÊTRE UTILISÉS COMME AGONISTES DU RÉCEPTEUR DE SPHINGOSINE-1-PHOSPHATE 1 (S1P1)
  申请人：GLAXO GROUP LTD

  公开号：WO2011072488A1

  公开（公告）日：2011-06-23

  Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptor are disclosed.

  氧代唑取代吲唑衍生物的化学式（I）或其药用盐具有药理活性，公开了它们的制备方法、含有它们的药物组合物以及它们在治疗由S1P1受体介导的各种疾病中的用途。
• OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS
  申请人：Bailey James

  公开号：US20120283297A1

  公开（公告）日：2012-11-08

  Oxadiazole substituted indazole derivatives of formula (I) or pharmaceutical salts thereof having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their uses in the treatment of various disorders mediated by S1P1 receptors are disclosed.

  氧代唑取代吲唑衍生物的化学式（I）或其药用盐具有药理活性，公开了它们的制备方法、含有它们的药物组合物以及它们在治疗由S1P1受体介导的各种疾病中的用途。
• [EN] ACETOPHENONE OXIME COMPOUND AND APPLICATION THEREOF<br/>[FR] COMPOSÉ OXIME D'ACÉTOPHÉNONE ET SON APPLICATION<br/>[ZH] 苯乙酮肟类化合物及其应用
  申请人：MEDSHINE DISCOVERY INC

  公开号：WO2022037525A1

  公开（公告）日：2022-02-24

  公开了苯乙酮肟类化合物及其制备方法，具体公开了式(II)所示化合物及其药学上可接受的盐。
• BENZO 2-AZASPIRO[4.4]NONANE COMPOUND AND USE THEREOF
  申请人：HELIOEAST PHARMACEUTICAL CO., LTD.

  公开号：EP4116294A1

  公开（公告）日：2023-01-11

  Disclosed are a series of benzo 2-azaspiro[4.4]nonane compounds, and specifically disclosed are a compound as represented by formula (P) or a pharmaceutically acceptable salt thereof.

  本发明公开了一系列的苯并-2-氮杂二环[4.4]壬烷化合物，具体而言，公开了一种如式(P)所示的化合物或其药学上可接受的盐。
• Navigating CYP1A Induction and Arylhydrocarbon Receptor Agonism in Drug Discovery. A Case History with S1P₁ Agonists
  作者：Simon J. Taylor、Emmanuel H. Demont、James Gray、Nigel Deeks、Aarti Patel、Dung Nguyen、Maxine Taylor、Steve Hood、Robert J. Watson、Rino A. Bit、Fiona McClure、Holly Ashall、Jason Witherington

  DOI：10.1021/acs.jmedchem.5b01102

  日期：2015.10.22

  This article describes the finding of substantial upregulation of mRNA and enzymes of the cytochrome P450 1A family during a lead optimization campaign for small molecule S1P(1). agonists. Fold changes in mRNA up to 10 000-fold for CYP1A1 in vivo in rat and cynomolgus monkey and up to 45-fold for GYP1A1 and GYP1A2 in vitro in rat and human hepatocytes were observed. Challenges observed with correlating induction in vitro and induction in vivo resulted in the implementation of a short, 4 day in vivo screening study in the rat which successfully identified noninducers. Subtle structure-activity relationships in this series of S1P(1) agonists are described extending beyond planarity and lipophilicity, and the impact and considerations of AhR and CYPIA induction in the context of drug development are discussed.